Table 3.
Results of multivariate logistic regression analysis of variables associated with recurrent PJI
| Variables | Multivariate model results | |
|---|---|---|
| Adjusted odds ratio (95% CI) | p | |
| 1st Albumin | 0.11 (0.04—3.81) | 0.342 |
| 2nd Albumin | 0.13 (0.02—3.21) | 0.231 |
| 3-stage revision arthroplasty or more | 35.02 (1.4—50.63) | < 0.001* |
| E. Coli | 3.67 (0.19—10.31) | 0.22 |
| ESBL-E. Coli | 12.33 (1.16—15.55) | < 0.001* |
| Fasting glucose, mmol/l | ||
| 100 to < = 200 | 1.58 (0.19—8.54) | 1 |
| > 200 | 2.16 (0.22—9.85) | 0.64 |
| 1st HbA1c ≥ 7 | 3.67 (0.21—3.21) | 0.32 |
| Last stage HbA1c ≥ 7 | 28.34 (1.2—40.12) | < 0.001* |
| Sulfonylurea (Glipizide, Glimepiride, Gliclazide) | 3.21 (0.25—11.24) | 0.34 |
| DPP4 inhibitor (Saxagliptin, Linagliptin, Alogliptin, Vildagliptin) | 2.58 (0.19—9.32) | 0.32 |
| Insulin combined with other OAD Insulin | 5.18 (0.28—13.36) | 0.12 |
| ACE inhibitor or ARB | 0.64 (0.09—8.95) | 1 |
PJI periprosthetic joint infection, E. Coli Escherichia coli, ESBL extended-spectrum beta-lactamases, HbA1c glycohemoglobin, DPP4 Dipeptidyl peptidase 4, OAD oral anti-diabetic drug, ACE angiotensin-converting enzyme, ARB angiotensin II receptor blockers, CI confidence interval
*p value < 0.05